Ryvu Therapeutics

Ryvu Therapeutics ROE

The Return on Equity (ROE) of Ryvu Therapeutics (RVU.WA) as of Nov 14, 2026 is -188.04 %. In the previous year, Return on Equity (ROE) was -77.45 % — a change of 142.79% (lower).

ROE

-188.04 %

YoY

142.79%

Last updated:

In 2025, Ryvu Therapeutics's return on equity (ROE) was -188.04 %, a 142.79% increase from the -77.45 % ROE in the previous year.

The Ryvu Therapeutics ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-0.06 PLN
Jan 1, 2019
-30.06 PLN
Jan 1, 2020
-14.16 PLN
Jan 1, 2021
-49.02 PLN
Jan 1, 2022
-24.40 PLN
Jan 1, 2023
-35.48 PLN
Jan 1, 2024
-77.45 PLN
Jan 1, 2025
-188.04 PLN
The Ryvu Therapeutics ROE history
YEARROEYoY
-188.04 %+142.79%
-77.45 %+118.27%
-35.48 %+45.43%
-24.40 %-50.23%
-49.02 %+246.13%
-14.16 %-52.88%
-30.06 %+54,157.83%
-0.06 %-100.54%
10.28 %+109.36%
4.91 %-63.61%
13.50 %-78.65%
63.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ryvu Therapeutics Stock analysis

What does Ryvu Therapeutics do? Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.

ROE Details

Decoding Ryvu Therapeutics's Return on Equity (ROE)

Ryvu Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Ryvu Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Ryvu Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Ryvu Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Ryvu Therapeutics stock

Return on Equity (ROE) of Ryvu Therapeutics is -188.04 % in 2025.

Return on Equity (ROE) of Ryvu Therapeutics changed from -77.45 % to -188.04 %, representing a 142.79% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Ryvu Therapeutics since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Ryvu Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Ryvu Therapeutics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Ryvu Therapeutics